NCT00033774 is a clinical trial in Sickle Cell, sponsored by National Heart, Lung, and Blood Institute (NHLBI).

Who is sponsoring NCT00033774?

NCT00033774 is sponsored by National Heart, Lung, and Blood Institute (NHLBI).

What condition does NCT00033774 study?

NCT00033774 studies Sickle Cell.

Is NCT00033774 still recruiting?

NCT00033774 is currently terminated. Last updated 25 August 2022.

Last reviewed 2022-08-25 · How we verify

NCT00033774

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Stem Cell Collection for Adult Volunteers

Terminated Last updated 25 August 2022

What this trial tests

trial in Sickle Cell in 136 participants. Terminated before completion.

Timeline

29 April 2002

Primary endpoint
27 June 2022

19 August 2022

Quick facts

Lead sponsor	National Heart, Lung, and Blood Institute (NHLBI)
Status	Terminated
Study type	OBSERVATIONAL
Enrollment	136
Start date	29 April 2002
Primary completion	27 June 2022
Estimated completion	19 August 2022
Sites	1 location across United States

Conditions studied

Sickle Cell — all drugs for Sickle Cell →

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Who can join

Adults 18 to 100, any sex, with Sickle Cell. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will examine the development of stem cells (very immature cells produced by the bone marrow) and their potential to change into cells of other organ types. These cells will be studied for their potential use in creating replacement tissue for diseases ranging from diabetes to Parkinson s. Healthy volunteers 18 years of age or older may be eligible for this study. Candidates will be screened with a medical history, physical examination, and blood tests. Participants will undergo a process called 'stem cell mobilization and apheresis' to collect bone marrow stem cells. For five days before the collection they will receive injections of a hormone called G-CSF, which stimulates release of stem cells from the bone marrow into the bloodstream. On the fifth day of the injections, stem cells will be collected through apheresis. For this procedure, blood is collected through a catheter (plastic tube) placed in an arm vein and directed into a cell separator machine. There, the white cells and stem cells are separated from the other blood components through a spinning process and collected in a bag inside the machine. The rest of the blood is returned to the donor through a catheter in the other arm.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Stem cell transplantation in neurological diseases: improving effectiveness in animal models.
Adami R, Scesa G, Bottai D. · · 2014 · cited 27× · PMID 25364724 · DOI 10.3389/fcell.2014.00017
Vasopressin stimulates the proliferation and differentiation of red blood cell precursors and improves recovery from anemia.
Mayer B, Németh K, Krepuska M, Myneni VD, et al · · 2017 · cited 23× · PMID 29187641 · DOI 10.1126/scitranslmed.aao1632

Verify or expand the search:

Other recruiting trials for Sickle Cell

Currently open trials in the same condition.

NCT06886477 — Sickle Cell, Pain and Mediterranean Diet · NA · recruiting
NCT07001189 — Impact of Regional Anesthesia on Inflammatory Mechanisms During Vaso-occlusive Crisis in Sickle Cell Patients · recruiting
NCT03685721 — Genotype -Phenotype Correlation of PKLR Variants With Pyruvate Kinase, 2,3-Diphosphglycerate and Adenosine Triphosphate · recruiting

Other National Heart, Lung, and Blood Institute (NHLBI) trials

Trials by the same sponsor.

NCT07566494 — Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07137455 — EDEN Intracardiac Electrogram Recording and Classifying System · NA · enrolling by invitation
NCT05372627 — NHLBI-Emory Advanced Cardiac CT Reconstruction · not yet recruiting
NCT07516379 — GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejecti · not yet recruiting
NCT06948097 — Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fost · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00033774 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Heart, Lung, and Blood Institute (NHLBI)
Last refreshed: 25 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00033774.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing